There remains little experimental evidence and no randomized clinical trial to date to confirm the benefit of platelet-rich plasma (PRP) for facial rejuvenation.
P latelet-rich plasma (PRP), a derivative of autologous whole blood that is thought to have particular woundhealing tissue regeneration properties, has entered the therapeutic armamentarium in dermatology. 1, 2 Preliminary work has investigated its effectiveness in the treatment of acne scars and androgenetic alopecia. 3 Given the widespread patient interest to improve the aging face, rejuvenation of facial skin is another potential application for PRP. There are few studies on the effect of PRP on photoaged skin, and those that are published are cohort studies [4] [5] [6] [7] without controls. Regardless of the dearth of research, PRP has emerged as a popular clinical phenomenon, with practitioners offering it to patients (often in combination with microneedling) for a range of purported benefits, including facial rejuvenation. The objective of this randomized clinical trial was to assess, via a placebo-controlled design, the effects of PRP on the physical appearance of photoaged facial skin.
Methods

Trial Design
This study was a parallel, split-face, randomized clinical trial with 1:1 allocation in which participants and raters were masked to participant groupings. There were no substantive changes to the study methods after trial commencement. The study was reviewed and approved by the Northwestern University institutional review board. This trial was performed under Investigational Device Exemption 14587 from the US Food and Drug Administration and was registered at ClinicalTrials.gov (NCT01372566). Written informed consent was obtained from participants. The trial protocol is available in Supplement 1.
Participants
Eligible participants, both male and female, were adults aged 18 to 70 years with bilateral cheek rhytids of Glogau class II or greater (ie, wrinkles "in motion"). Exclusions included the following: pregnancy or lactation, blood or platelet disorders, genetic disorders affecting fibroblasts or collagen, facial surgery or semipermanent dermal fillers within 1 year, history of herpes simplex infection, active skin disease or infection in the treatment area, history of hypertrophic scars or keloids, immunosuppressive disorders or disorders treated with immunosuppressive agents (including corticosteroids), and history of skin cancer or actinic keratosis, as well as topical or oral tretinoin, chemical peeling, botulinum toxin injection, or laser and light treatment for facial rhytids or rejuvenation within the past 6 months or planned in the next 3 months. Data were collected in the clinical research section of the dermatology clinical outpatient service at the Northwestern University medical center in Chicago, Illinois.
Interventions
At screening, after eligibility assessment and written informed consent were obtained, participants' demographic information and medical history were recorded, and laboratory testing (complete blood cell count, prothrombin time/partial thromboplastin time/international normalized ratio, liver function, and creatinine level) was performed. Those with abnormal laboratory values were not allowed to continue participation in the study.
At the first treatment visit, participants were instructed to avoid the use of any therapeutic agent for skin photoaging or rejuvenation and were provided sunscreen to apply to the whole face during the entire study period. Ten minutes after the face was washed at the study visit, baseline standardized digital photographs were obtained, and then inspection was conducted independently by 2 dermatologists (M.A. and K.P.), who assigned a photoaging score. Variations in scores were adjudicated by forced agreement. A topical anesthetic cream (EMLA; AstraZeneca) was applied to both cheeks approximately 1 hour before administration of the investigational product was to begin.
Venipuncture of a large peripheral vein was performed to collect blood from the participant. An autologous platelet concentrate procedure pack (SmartPrep 2 APC+; Harvest Technologies) and a blood processing centrifuge (SmartPrep 2 System; Harvest Technologies) were used to prepare the PRP sample. The blood sample was combined with acid citrate dextrose A, an anticoagulant, and spun in a centrifuge with 2 spins (a hard spin and a soft spin) to separate the PRP from the platelet-poor plasma. The remaining PRP was then injected into the cheek of the participant within the next 7 minutes. The complete method for venipuncture and preparation of PRP for injection is described in the eAppendix in Supplement 2.
Each participant received intradermal injections of PRP to one cheek and sterile normal saline (equivalent fluid volume) to the contralateral cheek. The investigational product-filled syringe exterior was opacified with tape, and participants' eyes were covered during injection of investigational product to maintain masking. Three milliliters of sterile normal saline was drawn from a single-use vial for injection to the allocated control side. Injections were performed 1 cm apart and at the level of the mid-dermis using a serial puncture technique with a 25-gauge needle. Aliquots of 0.02 mL per puncture were injected into the designated cheek from the zygomatic area to the mandibular area and from the nasolabial folds to the preauricular area, for a total of 3 mL per cheek. Immediately after injection, gentle pressure with gauze was applied for 5 minutes. The skin was then compressed with normal saline swabs for 15 minutes. For wound care, petrolatum-based emollients
Key Points
Question Do injections of platelet-rich plasma improve the appearance of photoaged facial skin?
Findings Based on this study of 27 participants in a randomized clinical trial who were masked to whether they received platelet-rich plasma or normal saline, the photoaged facial skin of those treated with platelet-rich plasma was found to be significantly less rough and wrinkled at 6 months after a single treatment.
Meaning Platelet-rich plasma, as administered within the conditions of this randomized clinical trial, is effective for facial rejuvenation, particularly for textural improvement of photoaged skin.
(Aquaphor Healing Ointment; Beiersdorf) were provided to each participant for daily home application for 7 days after injections.
At 2-week and 3-month follow-up study visits, digital photographs were again obtained as before, 2 dermatologists assigned photoaging scores based on these, each participant completed a self-assessment questionnaire, and adverse events were recorded. At the 6-month follow-up in addition to these procedures, participants completed an overall satisfaction questionnaire; in the event of an uneven contralateral outcome, participants were offered optional standard-of-care treatments for correction. At 12 months, a telephone follow-up was conducted with the participant to determine if he or she had any adverse events to report.
Outcomes
Primary outcome measures were photoaging scores for each cheek, as rated by 2 masked dermatologists at baseline, 2 weeks, 3 months, and 6 months, with consensus by forced agreement. Secondary outcomes included participant selfassessment scores of each cheek at 2 weeks, 3 months, and 6 months, whereby change in irregular pigmentation, skin texture, and wrinkles was rated on a 5-point scale designed to rate response, with 0 indicating worsening, 1 indicating no change, 2 indicating mild improvement, 3 indicating moderate improvement, and 4 indicating significant improvement. Participant overall satisfaction scores were reported at 6 months for each cheek on a 4-point scale, with 1 indicating not satisfied, 2 indicating slightly satisfied, 3 indicating moderately satisfied, and 4 indicating very satisfied. Adverse events at any time point reported by participants or observed by investigators were also recorded.
Sample Size
For the primary end point of the difference between PRP and normal saline in change at 2 weeks for any of the 4 photoaging subscores, a sample of 30 sites (15 individuals) would provide 80% power to detect an effect size of 0.85 at a type I error rate of 1.2% (adjusted for multiple comparisons) using the Wilcoxon signed rank test. The same effect size would be detected in comparing change from 2 weeks to 3 months to 6 months to determine if any change was sustained.
Randomization
The randomization sequence was generated using a computerized random number generator. The allocation concealment mechanism was designed so that the person generating the random allocation sequence (E.P.) was contacted via telephone by the person who was conducting the study visit (R.H., A.C., or A.G.) before each assignment, at which point one of us (E.P.) accessed the computer to obtain and then convey the assignment.
Masking
In this randomized clinical trial, participants and those assessing outcomes (dermatologist raters M.A. and K.P.) were masked to assignments for study interventions. Care providers (including injector D.P.W.) were not masked. To ensure that masking was successful, the interventions were as similar as possible: similar volumes of PRP and normal saline were injected at similar depth and with similar lateral spacing into cheek areas of similar size using similar syringes and needles.
Statistical Analysis
Photoaging scores, participant self-assessment scores, and participant overall satisfaction scores were analyzed using the Wilcoxon signed rank test. The threshold of statistical significance was 2-sided P = .05.
Results
The duration of the study spanned August 21, 2012, to February 16, 2016 . Of 27 participants enrolled in the study, 8 were discontinued from study participation (4 were lost to follow-up after screening and enrollment, 2 failed screening because of ≥1 abnormal laboratory result, 1 was lost to follow-up after study injections, and 1 withdrew because of intolerance to injections), and 19 completed the study per protocol and were analyzed for primary and secondary outcome measures (Figure) . (Table 2) .
Overall, participant self-assessment scores of improvement for pigmentation, texture, wrinkles, and telangiectasias were higher for PRP compared with normal saline at 6 months after injections, when participants rated the PRPtreated side as significantly more improved compared with the normal saline side for texture ( The PRP treatments for pigmentation and telangiectasias were both nominally but not significantly improved compared with normal saline at 6 months (Table 3) .
Discussion
Although this randomized clinical trial did not result in significant improvement through assessment of standardized photographs of photoaged cheek skin treated with injections of PRP compared with normal saline, the participants themselves rated 
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the PRP-treated side to be more improved, with significant improvement in both texture and wrinkles and a suggestion toward significant improvement in both pigmentation and telangiectasias. Participant overall satisfaction was also greater for PRP compared with normal saline. Participants, like the photograph raters, were also masked to minimize bias. While this was not designed to be a safety study, no serious adverse events were observed, and recorded skin effects were localized to the injection sites, were transient, and were fully remitting in the short term. The results of this study suggest that PRP for facial rejuvenation may at least temporarily improve the visual appearance of photoaged skin. Improvements may be subtle and difficult to detect for external raters relying on photographs, which may contain less information than live viewing. Participants may have been able to see differences more clearly because they knew their faces intimately and in great detail and had time to scrutinize their appearance at length and in close-up view (eg, by using magnification mirrors).
Methodologically, this randomized clinical trial was designed to minimize confounders. A randomized controlled design was used; in addition, the sham control was designed to be similar to the active treatment. Because of this design, it was possible to mask both participants and raters. Participantreported outcomes, which have increasingly displaced more paternalistic investigator ratings, 8 were thus valuable in this study because they were untainted by knowledge of which treatment had been received. The study was also adequately powered by using a split-face design to further limit interindividual differences. Finally, the study looked at outcomes as far out as 6 months to ensure that detected beneficial effects were not merely the result of possible confounding issues, such as transient wound healing and posttreatment edema obscuring wrinkles, smoothing texture, and concealing pigmentary abnormalities.
Limitations
A limitation to this study is that several participants terminated early, likely because of the follow-up visits required after a single treatment session visit. Furthermore, it could be argued that, instead of a single session only, multiple sessions of PRP injections to the targeted skin sites might have produced a greater and even cumulative benefit. The splitface design, while helpful in allowing patients to selfcompare treatment with control, may theoretically have decreased the difference between treatment and control to the extent that PRP had a remote effect even to the contralateral side of the face. There is no evidence for this last limitation because participants were clearly able to detect and report differences between both sides. Compared with prior work reported for PRP and facial rejuvenation, this study has reduced bias by design. Earlier work had predominantly looked only at the skin of those treated with PRP, with no comparator or control. 5 Also, measurements have often not been obtained by masked participants or investigators. Moreover, there has been a reliance on intermediate outcome measures, such as biochemical markers, histologic features, skin elasticity, and other clinical or physiological features detected by devices, rather than the visual appearance of skin features as rated by humans. 4 The present study was designed specifically to correct for these deficiencies. As has been suggested, 9 a criterion standard for aesthetic procedures is visible change noticeable by the patient.
Conclusions
This is, to our knowledge, the first study to date of participants in a randomized clinical trial who did not know if they received PRP or normal saline, and the findings suggest that PRP may have benefit for reducing the visible signs of photoaging, particularly because they were detectable by the participants themselves 6 months after a single treatment session. It remains to be seen how long the benefit of such treatment may last and to what extent repeat sessions of PRP administration can maximize the extent and/or persistence of effect. Larger studies are warranted to also enable subgroup analyses that show which particular types of patients may see the best results. In the meantime, it is reassuring that some of the optimism reported for earlier open-label studies has now been borne out in a controlled investigation. 
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STUDY OBJECTIVES
The primary objective of this study is to evaluate the effect of autologous platelet-rich plasma in the treatment of photoaging.
STUDY DESIGN
This is a prospective randomized controlled split face study that will evaluate the effect of autologous platelet-rich plasma on photoaged skin, specifically, fine lines, mottled pigmentation, tactile roughness, and sallowness. Subjects who meet the inclusion and exclusion criteria will be enrolled in this study. The subjects will be randomly assigned to receive one treatment session in which one side of the cheek will be treated with intradermal autologous platelet-rich plasma and the other side of will be treated with a normal saline intradermal injection as a control. Two blinded dermatologists will inspect the skin and provide a photoaging score. Standard digital and UVA photographs to evaluate skin surface morphology and photoaging will be taken. Evaluation and photos will take place during the treatment visit (before treatment), at the 2 week visit, and 3 and 6 months after treatment. The subjects will perform a blind self-assessment at the 2 week visit, and 3 and 6 month after treatment. Adverse events will be recorded. A telephone call at 12 months will also assess adverse events.
BACKGROUND AND RATIONALE
Platelets are anucleated cells that are derived from megakaryocytes in the bone marrow. The normal concentration of platelets in blood is approximately 140,000 to 400,000/mm 3 . Inside platelets, there are three types of platelet secretory granules: α-granules which are most abundant, dense granules, and lysosomes. 1 Numerous proteins that strongly influence wound healing are contained within the α-granules of platelets, including platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, interleukin (IL)-1, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet-derived endothelial growth factor (PDEGF), epithelial cell growth factor (ECGF) and insulin-like growth factor (IGF). [1] [2] [3] Platelets are the first cells to appear after injury when damaged blood vessel walls expose the underlying collagen and extracellular matrix. Platelets are activated at the site of blood vessel injury by locally generated thrombin. During activation, the α-granules within platelets fuse with the platelet plasma membrane and release some of their protein contents to their surroundings, a process called degranulation. Secretory proteins are transformed to a bioactive state and secreted. Active proteins then bind to the transmembrane receptors of target cells e.g. mesenchymal stem cells, osteoblast, fibroblasts, endothelial cells, and epidermal cells. 3 Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma. 4 An 8-fold increase in platelet concentration was found in the platelet-rich plasma compared with that of whole blood. [5] [6] It is not only a concentration of platelets, but also a concentration of at least 7 fundamental protein growth factors proven to be actively secreted by platelets. These growth factors include 3 isomers of platelet-derived growth factor (PDGFαα, PDGFββ, and PDGFαβ), 2 of the numerous transforming growth factors-β (TGFβ1 and TGFβ2), vascular endothelial growth factor, and epithelial growth factor. [5] [6] [7] However, growth factor concentrations vary from patient to patient. The cytokines play important roles in cell proliferation, chemotaxis, cell differentiation, and angiogenesis. In addition, the platelets in PRP are delivered to the site of a clot, which contains several cell adhesion molecules including fibronectin, fibrin, and vitronectin. These cell adhesion molecules aid in cell migration by acting as scaffolding upon which cells adhere and begin the wound healing process. There is no standard recommendation for the concentration of platelets in platelet-rich plasma over baseline. Marx 4 suggested that a PRP platelet count of 1 million/μL in 6-mL of plasma is therapeutic PRP. Some investigators have suggested that platelet-rich plasma should achieve a 3 to 5-fold increase in platelet concentration over baseline. Weibrich et al. 8 suggest that different individuals may require different platelet concentration ratios to achieve a comparable biological effect.
Preparation of PRP begins by addition of citrate to whole blood to bind the ionized calcium and inhibit the clotting cascade. Citrate phosphate dextrose (CPD) or acid citrate dextrose (ACD) is generally used as an anticoagulant. Blood is collected with anticoagulant and is immediately processed by 2 centrifugation steps. The first step (hard spin) separates the blood into three layers: red blood cells (specific gravity1.09) at the bottom, platelet-poor plasma (specific gravity 1.06) as the supernatant, and a buffy coat layer (specific gravity 1.06) consisting of platelets and white blood cells in between. The second (soft) spin is an attempt to discard both the RBC layer and the platelet-poor plasma (PPP) to collect only the buffy coat layer, which settle sat the bottom because of its high specific gravity. 9 (Fig.1 ) Finally, to activate platelets in order to release growth factors from platelet α-granules, calcium chloride and thrombin will be added to the platelet concentrate. Thrombin directly activates platelets and calcium ions replenish the calcium that was bound to the acid citrate dextrose anticoagulant. 3 (Fig.2) The PRP must then be clotted to allow for delivery to the desired site. Platelets begin actively secreting these proteins about10 minutes after clotting, with more than 95% of the pre-synthesized growth factors secreted within 1 hour. Platelets continue to synthesize and secrete additional growth factor for the remaining 7 days of their life span. 4 Fig . 1 Classical manual platelet-rich plasma protocol using a two-step centrifugation procedure. 10 The use of PRP was proposed to provide a microenvironment for the orchestration of the sequential process of hard and soft tissue regeneration involving migration, proliferation and differentiation of mesenchymal cells. In recent years, the application of platelet-rich plasma has been widely extended in diverse medical and surgical procedures, especially in the fields of wound healing, orthopedic surgery, 11 periodontic surgery, 12 maxillofacial surgery, [13] [14] plastic surgery, [15] [16] [17] thoracic surgery, [18] [19] and ophthalmology. [20] [21] In a meta-analysis of oral and maxillofacial surgery which analyzed four studies with 153 patients suffering from chronic periodontitis, a significant improvement in depth reduction was seen in the group treated with PRP. These results suggest that patients with severe chronic periodontitis could benefit from PRP. [22] [23] [24] A systematic review found that treatment of skin ulcers with PRP increased the percentage of total recovery but the results were not statistically significant. 24 Powell and colleagues 25 used a split-face study design where each side of face received either experimental PRP or control. This was a randomized controlled trial using autologous PRP in patients undergoing face-lifts. The patients that received PRP after face-lift surgery showed decreased ecchymosis and edema compared to the control group, although results were not statistically significant. Recently, Redaelli and colleagues 26 published a case series of 23 consecutively treated patients with PRP injection into the face and neck. The results were evaluated by photos taken from a dermoscope connected to a digital camera. The average improvement was 'moderate to good' and every patient was satisfied with the overall quality of the treatment. In addition, patients observed that acne scars in the treated areas also improved.
Skin photoaging refers to the effects of long-term ultraviolet exposure and sun damage superimposed on intrinsically aged skin. 27 The clinical signs of photoaging are fine lines, dyspigmentation, skin laxity, yellow hues, wrinkles, and telangiectasias. Histologically, photodamage is manifested as the disorganization of collagen fibrils and the accumulation of [28] [29] In addition, collagen production is reduced and collagen degradation is increased in photoaged skin. Activator protein-1 (AP-1) and transforming growth factor (TGF-β) are involved in this UV-mediated down-regulation of collagen synthesis. There is a decreased expression of TGF-β, an important promoter of collagen synthesis, and its receptor throughout the epidermis and dermis after UV irradiation. 27 UV light also causes damage to collagen and other skin structures through the formation of free radicals. Similar to wound healing, this cellular damage from free radicals is repaired, but in photodamaged skin, the damage from free radicals occurs over time and the injury is ongoing due to continued exposure to UV light. Photodamaged skin may thus be thought of as a chronic wound. A pilot study evaluated topical application of a combination of growth factors and cytokines and the effect on photoaged skin. 11 out of 14 patients showed clinical improvement in at least one facial area and a significant change in objective measurements by optical profilometry indicating a decrease in the depth and number of fine lines. In addition, new collagen formation was observed in biopsy specimens. 30 Repair of photodamaged skin involves the same mechanisms as wound repair, making the enhancement of this process by topical growth factors seems logical.
PRP can be prepared either by a blood bank or by point-of-care table top devices. Compared to table top devices, the preparation of PRP by blood banks through discontinuous plasmapheresis methods might be limited because of higher production costs, multiple transfers, required larger volumes of blood, and the delayed availability of PRP. With table top devices, a similar protocol of a hard and soft spin are followed. Standard cell separators and salvage devices can be used to produce platelet-rich plasma. These devices operate on a unit of blood and typically use a continuous-flow centrifuge bowl or continuous-flow disk separation technology and both a hard (fast) and a soft (slow) spin, yielding platelet concentrations 2-4 times greater than baseline.
The majority of clinical trials reported encouraging outcomes of autologous platelet-rich plasma, but to date there is no randomized controlled clinical trial which can provide evidence of PRP in dermatology. This study will determine whether the intradermal injection of autologous platelet-rich plasma results in the reversal of facial photodamage.
STUDY POPULATION 4.1 Inclusion criteria
1. Subjects of either sex (Male or Female), 18-70 years old. 2. Subjects are in good health. 3. Bilateral cheek wrinkles "in motion" with severities of ≥ type II of Glogau photoaging classification (APPENDIX I). 4. Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator. 5. Subject requests cosmetic improvement of facial wrinkles.
Exclusion criteria
1. Pregnant or lactating. 2. Subjects who are unable to understand the protocol or to give informed consent.
3. Subjects who have a history of blood or platelet disorders e.g. anemia, thrombocytopenia, coagulopathy, hypofibrinogenemia, or are on anticoagulant or anti-platelet therapy. 4. Subjects who have had topical or oral tretinoin, chemical peeling, botulinum toxin injection or laser and light treatment for facial rhytides or rejuvenation within past 6 months or planning to undergo treatments as described in the next 3 months. 5. Facial surgery in the lower 2/3 of the face or semi-permanent dermal fillers within 1 year prior to study enrollment 6. Subjects who have history of recurrent facial or labial herpes simplex infection. 7. Subjects who have active skin disease or skin infection in treatment area. 8. Subjects who are allergic to lidocaine or prilocaine. 9. Subjects who have a history of hypertrophic scars and keloids. 10. Subjects who have any requirement for the use of local or systemic steroids or immunosuppressive agents. 11. Subject notes that he/she is HIV positive 12. Subjects with history of skin cancer or actinic keratosis 13. Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations. 14. Skin conditions that interfere with wrinkle assessment/treatment (excessive dermatochalasis, inability to lessen the wrinkles by physically spreading the area apart). 15. Excessive exposure to the sun, such as jobs requiring constant outdoor exposure. 16 . Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, etc.
Criteria for terminating study participation
Subject wishes to stop being in the study Subject no longer qualifies based on inclusion/exclusion criteria Adverse events occur that, in the opinion of the investigator, put the subject at increased risk and it is not in the best interest of the subject to continue the study
Recruiting/Screening
The investigator will select subjects presenting to the Department of Dermatology Clinic at Northwestern University who meet the inclusion criteria. Those expressing an interest in the study will be contacted for a verbal explanation of the protocol by an investigator. Written announcements for participation in the study will also be posted on the internet and around the Northwestern University Feinberg School of Medicine. Volunteer participants will come for a screening visit. If they meet inclusion/exclusion criteria, the participant will be consented. Consent for participation will be obtained in writing by signature on a consent form by the study staff. Before consent, the consent will be read by the subject and the subject will be encouraged to ask any questions for clarification. A copy of the subject's signed consent form will be retained in the study file.
STUDY PROCEDURES
Screening visit
Subjects who meet the inclusion/exclusion criteria will be enrolled and consented. The subject's demographic data, medical history, and current usage of any topical drug or cream on the face will be recorded. Appropriate laboratory testing will be performed (CBC, PT/PTT/INR, liver function, creatinine). All blood will be taken to the Northwestern Memorial Hospital Laboratories on the 18 th floor of the Galter Pavilion or the 2 nd floor of Arkes Pavilion for processing and storage.
Treatment Visit
Laboratory results from screening visit will be reviewed. If all labs are within normal limits, the subject will proceed to the treatment phase. If not, the subject will be withdrawn from the study. Subjects will be permitted to apply their usual skin care products and will be requested not alter their usual routine skin care during the study period. Subjects will be instructed to avoid the use of any therapeutic agents for photoaging or rejuvenation of the skin during the study period. Baseline digital and UV-A photographs (en face and 45 oblique) will be taken. Two dermatologists will inspect these photos in order to assign a photoaging score. Subjects will receive sunscreen to apply to the whole face during the study period. Adverse events will be recorded.
Treatment randomization
Before the study begins, a random number table will be generated for each study participant according to subject number. The number will indicate whether treatment or control will be taken on the right cheek. "0" represents intradermal injection with sterile normal saline whereas "1" represents intradermal injection with autologous platelet-rich plasma.
Standard digital photographing will be performed in the same location for standardized en face and 45 oblique views of both sides of face at each visit. The subjects will be photographed 10 minutes after the face is washed. Photos will be taken with a standard clinic camera using ambient lighting for one set of photos per subject and then ultraviolet A lighting for a second set of photos per subject at all visits that indicate photos will be taken A topical anesthetic (EMLA, a 5% emulsion preparation, containing 2.5% each of lidocaine and prilocaine, AstraZeneca, Wilmington, DE, USA) will be applied to both cheeks approximately one hour before the treatment begins. Each subject will receive an intradermal injection of platelet-rich plasma on one cheek and an intradermal injection of sterile normal saline on the other cheek.
A Procedure sterile pack is intended for use with the SmartPReP Platelet Concentrate System.
• All of the following processes will be performed strictly following aseptic techniques.
• Subject's blood will be drawn just prior to start the procedure.
SmartPReP Procedure Pack includes:
19-gauge butterfly catheter Acid citrate dextrose-A anticoagulant A 20 ml syringe for the blood draw 2 10 ml syringes: one for the platelet-poor plasma draw which will be discarded, one for the platelet-rich plasma Process disposable (PD) Sterile plastic cup 
Preparation of the venipuncture site
A suitably large peripheral vein free of lesions will be selected, typically the antecubital vein.
1. Blood will be drawn by using a 19-gauge butterfly access catheter to avoid trauma to platelets.
2. Tourniquet will be applied and a venipuncture site will be identified. 3. The area at least 4 cm in all direction from the intended site of venipuncture will be scrubbed with an aqueous solution of iodophor compound for a minimum of 30 seconds. 4. The area will be covered with dry, sterile gauze and this area will not be touched again until venipuncture.
Process
Steps for platelet-rich plasma 1. Draw 3 ml of acid citrate dextrose A (ACD-A) as an anticoagulant in a 20 ml syringe.
2. Transfer 1 ml ACD-A from the 20 ml syringe into the Plasma Chamber of the Process Disposable (PD) 3. Draw venous blood using acid a citrate dextrose-A (ACD-A) syringe to the ¾ oz mark (approximately 22 ml).
4. Transfer total syringe volume into the blood chamber of the PD (red port).
5. Load the SmartPReP® with the PD, close the lid, and press the green start button. To prevent system imbalance, the correct balance weight will be used.
The first spin (hard spin) will separate red blood cells from the plasma that contains platelets, white blood cells, and clotting factors. The second spin (soft spin) will finely separate the platelet concentrate (PRP) from the platelet poor plasma (PPP). The dual spin will be in one time in the separation system. Remove PD(s) when cycle is complete.
7. Using a new syringe without the spacer, resuspend the platelet-rich plasma with remaining PPP.
8. The final 3 ml of autologous platelet-rich plasma will be immediately injected to the subjects within next 7 minutes.
Injection techniques and wound care
Injections will be performed intradermally (approximately at the level of the mid-dermis) using a serial puncture technique with a 25-gauge needle. Injections should be approximately 1 cm apart.
Aliquots of approximately 0.02 ml per puncture will be placed on the designated cheek from zygomatic area to the mandibular area and from the nasolabial folds to the preauricular areas. The investigator will prepare 3 ml of sterile normal saline and inject the contralateral cheek in the same manner. The subject's eyes will be covered during the procedure in order that they remain blinded to the procedure so that they may do a blinded self-assessment at a later visit. Immediately after treatment, the skin will have minimal bleeding and serum secretion that will be controlled by gentle pressure with gauze for five minutes. The skin will then be soaked with saline swabs for 15 minutes. For wound care, Aquaphor healing ointment (Eucerin®, Beiersdorf company Germany)
will be recommended for continual application for 7 days post-treatment.
6. After processing, use the syringe with spacer and withdraw platelet-poor plasma (PPP) from white port until air bubbles are present. Discard the syringe of PPP.
Follow up visits
• 2 week follow up visit Digital and UV-A photographs (en face and 45° oblique) will be taken. Two dermatologists will inspect these photos in order to assign a photoaging score. Subjects will complete a self-assessment questionnaire. Adverse events will be recorded.
• 3 month follow up visit Digital and UV-A photographs (en face and 45 oblique) will be taken.Two dermatologists will inspect these photos in order to assign a photoaging score. Subject will complete a self-assessment questionnaire. Adverse events will be recorded.
• 6 month follow up visit Digital and UV-A photographs (en face and 45 oblique) will be taken. Two dermatologists will inspect these photos in order to assign a photoaging score. Subject will complete a self-assessment questionnaire. Subject will complete an overall subject satisfaction questionnaire. In the event of an uneven response, subject will be offered an optional standard of care treatment chemical peel (standard of care treatment) to treat the unevenness of the skin. Adverse events will be recorded.
7.1 Harvest PRP Separation System is a table-top centrifuge previously approved by the FDA. It is a table-top, closed process system, with a self-decanting, swinging bucket centrifuge and processing disposable designed to allow rapid automatic separation of plasma and platelets. It is used for the safe and rapid preparation of autologous platelet-rich plasma from a small sample of blood at the patient's point of care. Fig.3 Harvest PRP Separation System
DATA DISCLOSURE AND SUBJECT CONFIDENTIALITY
Subject medical information obtained as a result of this study is considered confidential and disclosure to third parties other than the principal investigator and the co-investigators is prohibited. All reports and communications relating to subjects in this study will identify each subject only by their initials and study identification number. Medical information resulting from a subject's participation in this study may be given to the subject's personal physician or to the appropriate medical personnel responsible for the subject's welfare. Data generated as a result of this study are to be available for inspection upon request by the Food and Drug Administration, other government regulatory agency auditors, and the Northwestern University Institutional Review Board (IRB). The information developed in this clinical study will be used to reassess the treatments for photoaging of the skin.
EFFICACY ASSESSMENT
Efficacy Assessment will be done based on the primary and secondary outcome measures mentioned above.
SAFETY ASSESSMENT
Because of its autologous origin, PRP does not hold any risk of immunological reaction or transmissible diseases. Risks from needle injection include transient pain, bleeding, bruising, and hyperpigmentation. Bleeding is usually easily stopped with compression. Subjects will be given instructions for proper wound care and phone numbers for answering any questions. Treatment for adverse events will be per standard of care from dermatologists in the Department of Dermatology or at the subject's physician of choice. The subject will be financially responsible for these treatments.
STATISTICAL CONSIDERATIONS
Data will be analyzed under the supervision of Mary Kwasny, ScD, in the Department of Preventive Medicine. With a sample of 30 patients, we are limited to non-parametric testing, however, as the patients undergo both the PRP and Saline, we should have adequate power to detect any clinically relevant differences.
Primary Outcome
For the primary endpoint of difference between PRP and Saline in change at 2 weeks for any of the 4 photoaging subscales, a sample of 30 individuals will provide 80% power to detect an effect size of 0.85 at type I error rate of 1.2% (adjusted for multiple comparisons) using Wilcoxon Sign Rank tests. The same effect size would be detected in comparing change from 2 weeks to 3 months to 6 months to determine if any change is sustained.
Secondary Outcomes
For differences between self-assessment, or satisfaction, a sample of 30 patients will provide 80% power to detect effect sizes as small as 0.68 using Wilcoxon Sign Rank tests at a type I error rate of 5%. Similar power/effect sizes will be detectable in determining if the change in either of these measures is sustainable at 3 and 6 months.
Fisher's exact test will be used to determine if the rate of any adverse events (if reported) differs between PRP and Saline. Assuming independence, if the rate of an adverse event is 3% (1/30) in the control group, we have 80% power to detect rates in the PRP group of 30% (9/30). Regardless, any adverse events will be reported.
STUDY SITES
Northwestern University Dermatology Clinic 676 N. St. Clair Street, Suite 1600, Chicago, IL 60611
ETHICAL CONSIDERATIONS
Human Subjects Protection
A periodic review must be submitted to the IRB at least once per year. The IRB must be notified of completion of the study. After study completion or termination, a final report must be provided to the IRB to close the study. The investigator must maintain an accurate and complete record of all submissions made to the IRB, including a list of all reports and documents submitted. Adverse events that are reported to the FDA as IDE Safety Reports must be submitted promptly to the IRB per IRB guidelines.
At least once per year, the IRB must review and give written approval in order to continue the study. This trial will be conducted in accordance with Good Clinical Practices and the Declaration of Helsinki.
Consent Form
Prior to study entry, a written informed consent must be obtained from the subject. A copy of the subject's signed consent form must be retained in the study file.
Protocol Amendments
All changes must be submitted to the IRB. Protocol modifications that impact subject safety or the validity of the study must be approved by the IRB before initiation.
Retention of Records
Food and Drug Administration and Good Clinical Practice guidelines require that an Investigator retain subject identification codes, subject files, and source data for the maximum period of time permitted by the hospital, institution, or private practice, but not less than 15 years after the completion or discontinuation of the trial.
Use of Information and Publication
The Principal Investigator or sub-investigators may publish the results of this study in conjunction with appropriate scientific and medical personnel.
